Trial reportArthritis research & therapy2026
Circulating immune cell biomarkers in Psoriatic Arthritis: associations with clinical manifestations and treatment response in the TOFA-PREDICT trial.
Trial report in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundTo investigate the associations of circulating immune cell biomarkers with clinical manifestations and treatment response in Psoriatic Arthritis (PsA), and to evaluate whether these biomarkers improve prediction of individual response to tofacitinib, methotrexate, or etanercept.
methodsData from the TOFA-PREDICT development cohort (n = 80) were used. DMARD naïve patients were randomized to tofacitinib or methotrexate, and csDMARD inadequate responders were randomized to tofacitinib or etanercept. Treatment response (achievement of Minimal Disease Activity) was scored at week 16. Clinical data and peripheral blood mononuclear cells were analyzed at baseline and week 16. Relevant biomarkers for clinical manifestations or treatment response were selected using sparse partial least squares (sPLS) regression and extreme gradient boosting. Associations with PsA clinical manifestations were analyzed using multivariate linear regression. Biomarker profiles for treatment response were derived by sPLS regression. Lastly, a Ridge regression model was used to evaluate whether selected biomarkers improved the prediction of individual treatment response beyond a previously developed clinical model.
resultsThe biomarkers explained up to 27% and 11% of observed variance for psoriasis severity and the swollen joint count, respectively. Baseline biomarker profiles classified etanercept and methotrexate responders relatively well, but did not distinguish tofacitinib responders. Adding biomarker data to clinical data did not improve the accuracy of individual response prediction (AUC-ROC 0.74).
conclusionOur comprehensive set of circulating immune cell biomarkers showed no additional value in precision medicine, when added to clinical predictors. However, the observed associations provide relevant insights into pathophysiological mechanisms underlying differential treatment response and clinical manifestations.
trial registrationEudraCT Trial registration number 2017-003900-28, registration date January 25th 2018.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.